325 related articles for article (PubMed ID: 6225504)
1. Immunologic dysfunction in patients with classic hemophilia receiving lyophilized factor VIII concentrates and cryoprecipitate.
Tsoukas C; Gervais F; Fuks A; Guttmann RD; Strawczynski H; Shuster J; Gold P
Can Med Assoc J; 1983 Oct; 129(7):713-7. PubMed ID: 6225504
[TBL] [Abstract][Full Text] [Related]
2. T-cell alterations in hemophiliacs treated with commercial clotting factor concentrates.
Lechner K; Niessner H; Bettelheim P; Deutsch E; Fasching I; Fuhrmann M; Hinterberger W; Korninger C; Neumann E; Liszka K
Thromb Haemost; 1983 Aug; 50(2):552-6. PubMed ID: 6314582
[TBL] [Abstract][Full Text] [Related]
3. [Hemophilia and HTLV-III infection].
Lechler E
Z Hautkr; 1986 Dec; 61(23):1687-704. PubMed ID: 2949442
[TBL] [Abstract][Full Text] [Related]
4. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
Brinkhous KM
Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
[TBL] [Abstract][Full Text] [Related]
5. AIDS in a patient with hemophilia receiving mainly cryoprecipitate.
Gerstein HC; Fanning MM; Read SE; Shepherd FA; Glynn MF
Can Med Assoc J; 1984 Jul; 131(1):45-7. PubMed ID: 6428732
[TBL] [Abstract][Full Text] [Related]
6. T-lymphocyte subpopulations in patients with classic hemophilia treated with cryoprecipitate and lyophilized concentrates.
Menitove JE; Aster RH; Casper JT; Lauer SJ; Gottschall JL; Williams JE; Gill JC; Wheeler DV; Piaskowski V; Kirchner P; Montgomery RR
N Engl J Med; 1983 Jan; 308(2):83-6. PubMed ID: 6401196
[No Abstract] [Full Text] [Related]
7. Immunologic studies in asymptomatic hemophiliac patients.
Frydecka I; Kowalewska B; Lesiecki A; Kuliczkowski K; Palakowska A; Polkowski A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(5):708-15. PubMed ID: 2435638
[TBL] [Abstract][Full Text] [Related]
8. Impaired cell-mediated immunity in patients with classic hemophilia.
Lederman MM; Ratnoff OD; Scillian JJ; Jones PK; Schacter B
N Engl J Med; 1983 Jan; 308(2):79-83. PubMed ID: 6216408
[No Abstract] [Full Text] [Related]
9. Immunological alterations in haemophiliacs treated with lyophilized Factor VIII cryoprecipitate from volunteer donors.
Ceuppens JL; Vermylen J; Colaert J; Desmyter J; Gautama K; Stevens E; The AL; Vanham G; Vermylen C; Verstraete M
Thromb Haemost; 1984 Apr; 51(2):207-11. PubMed ID: 6429883
[TBL] [Abstract][Full Text] [Related]
10. Correction by factor VIII of decreased neutrophil alkaline phosphatase activity in classic haemophilia and von Willebrand's disease.
Janković GM; Janosević S
Haematologia (Budap); 1978-1979; 12(1-4):183-8. PubMed ID: 317061
[TBL] [Abstract][Full Text] [Related]
11. Immunologic studies in asymptomatic hemophilia patients. Relationship to acquired immune deficiency syndrome (AIDS).
Landay A; Poon MC; Abo T; Stagno S; Lurie A; Cooper MD
J Clin Invest; 1983 May; 71(5):1500-4. PubMed ID: 6222070
[TBL] [Abstract][Full Text] [Related]
12. Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate.
Schimpf K; Brackmann HH; Kreuz W; Kraus B; Haschke F; Schramm W; Moesseler J; Auerswald G; Sutor AH; Koehler K
N Engl J Med; 1989 Oct; 321(17):1148-52. PubMed ID: 2507917
[TBL] [Abstract][Full Text] [Related]
13. Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate.
Allersma DP; Smid WM; van der Does JA; van der Meer J; Briët E
Thromb Haemost; 1996 Feb; 75(2):261-6. PubMed ID: 8815573
[TBL] [Abstract][Full Text] [Related]
14. HTLV-I antibody status in hemophilia patients treated with factor concentrates prepared from U.S. plasma sources and in hemophilia patients with AIDS.
Chorba TL; Jason JM; Ramsey RB; Lechner K; Pabinger-Fasching I; Kalyanaraman VS; McDougal JS; Cabradilla CD; Tregillus LC; Lawrence DN
Thromb Haemost; 1985 Apr; 53(2):180-2. PubMed ID: 2992112
[TBL] [Abstract][Full Text] [Related]
15. Impaired cell-mediated immunity in hemophilia. II. Persistence of subclinical immunodeficiency and enhancement of natural killer activity by lymphokines.
Lederman MM; Ratnoff OD; Schacter B; Shoger T
J Lab Clin Med; 1985 Aug; 106(2):197-204. PubMed ID: 2410523
[TBL] [Abstract][Full Text] [Related]
16. Acid-labile alpha interferon. A possible preclinical marker for the acquired immunodeficiency syndrome in hemophilia.
Eyster ME; Goedert JJ; Poon MC; Preble OT
N Engl J Med; 1983 Sep; 309(10):583-6. PubMed ID: 6410234
[TBL] [Abstract][Full Text] [Related]
17. AIDS and preventive treatment in hemophilia.
Desforges JF
N Engl J Med; 1983 Jan; 308(2):94-5. PubMed ID: 6216409
[No Abstract] [Full Text] [Related]
18. Abnormality of helper/suppressor T cell ratio in patients with hemophilia.
Yasuda K; Matsumoto K; Okubo K; Yokoyama MM; Hiyoshi Y; Natori H
J Clin Lab Immunol; 1985 Jan; 16(1):27-30. PubMed ID: 2984427
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of lyophilized cryoprecipitate in hemophilia A.
Chuansumrit A; Isarangkura P; Chantanakajornfung A; Kuhathong K; Pintadit P; Jitpraphai C; Hathirat P; Nuchprayoon C
J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S69-73. PubMed ID: 10730521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
